1-(5,5,8,8-四甲基-5,6,7,8-四氢萘-2-基)乙烷-1-酮 | 17610-21-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 1-(5,5,8,8-四甲基-5,6,7,8-四氢萘-2-基)乙烷-1-酮
• 英文名称: 1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)ethanone
• 英文别名: 1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethanone；1-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone；1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone
• CAS: 17610-21-8
• 化学式: C₁₆H₂₂O
• mdl: MFCD00052727
• 分子量: 230.35
• InChiKey: IHUSZOMIBSDQTB-UHFFFAOYSA-N

物化性质

• 熔点：
  26-27 °C(Solv: methanol (67-56-1))
• 沸点：
  98 °C
• 密度：
  0.941±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.562
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2914399090
• 危险性防范说明：
  P501,P270,P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313,P301+P312+P330
• 危险性描述：
  H302,H315,H319
• 储存条件：
  2-8℃，应密封保存，并置于干燥处。

SDS

Name:	1-(5 5 8 8-Tetramethyl-5 6 7 8-tetrahydron Material Safety Data Sheet
Synonym:	7-Acetyl-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl nafthalen
CAS:	17610-21-8

Section 1 - Chemical Product MSDS Name:1-(5 5 8 8-Tetramethyl-5 6 7 8-tetrahydron Material Safety Data Sheet
Synonym:7-Acetyl-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl nafthalen

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17610-21-8	1-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahy		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17610-21-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid above room te
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 98 - 100 deg C @0.2mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C16H22O
Molecular Weight: 230

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, amines.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17610-21-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydron aphthalen-2-yl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 17610-21-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17610-21-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17610-21-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(5,5,8,8-四甲基-5,6,7,8-四氢萘-2-基)乙烷-1-酮 在 吡啶 四氢呋喃 、 氢氧化钾 、 sodium tetrahydroborate 、 三溴化磷 作用下， 以 甲醇 、 乙醚 、 乙醇 、 正己烷 、 水 、 xylene 为溶剂， 反应 67.0h， 生成 芳维甲酸
  参考文献：
  名称：

  Loeliger; Bollag; Mayer, European Journal of Medicinal Chemistry, 1980, vol. 15, # 1, p. 9 - 15

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-二氯-2,5-二甲基己烷 在 三氯化铝 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 生成 1-(5,5,8,8-四甲基-5,6,7,8-四氢萘-2-基)乙烷-1-酮
  参考文献：
  名称：

  视黄苯甲酸。1.芳族酰胺与类视色素活性的结构-活性关系。

  摘要：

  已显示两种类型的芳族酰胺，对苯二甲酸单苯胺和（芳基甲酰胺基）苯甲酸具有有效的类维生素A活性，可以归类为类维生素A。基于对人早幼粒细胞白血病细胞HL-60的分化诱导活性，讨论了这些酰胺的构效关系。在通式4（X ＝ NHCO或CONH）中，引起类视色素活性的必要因素是在其间位的中等尺寸烷基（异丙基，叔丁基等）和在其对位的羧基。另一个苯环。酰胺结构的键可以颠倒，该部分显然具有将两个苯环相对于彼此定位在适当位置的作用。推测是由于所得的构象变化，在酰胺基邻位的环位置取代或酰胺基的N-甲基化导致活性降低。显然，苄基甲基和羧基的相互取向以及它们之间的距离是决定类视色素活性的必要因素。在合成的化合物中，4-[（（5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基）氨基甲酰基]苯甲酸（Am80）和4-[（5,6，在该测定中，7,8-四氢-5,5,8,8-四甲基-2-萘基[羧酰胺基]苯甲酸（Am580）的

  DOI：

  10.1021/jm00119a021

文献信息

• General Synthesis of Retinoids and Arotinoids via Palladium-Catalyzed Cross-Coupling of Boronic Acids with Electrophiles
  作者：Alicia Torrado、Susana López、Rosana Alvarez、Angel R. de Lera

  DOI：10.1055/s-1995-3905

  日期：1995.3

  A novel approach to the synthesis of retinoids and arotinoids (including heterocyclic analogs) is described which is based on the thallium-accelerated palladium-catalyzed cross-coupling of boronic acids with a variety of electrophiles (the Suzuki reaction).

  本文介绍了一种制备类视黄醇和阿洛视黄醇（包括杂环类似物）的新方法，该方法基于铊促进的钯催化下硼酸与多种亲电试剂的交叉偶联合成反应（Suzuki反应）。
• Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
  申请人：Akerman Michelle

  公开号：US20070066647A1

  公开（公告）日：2007-03-22

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L 1 , L 2 , M, X, L 3 , and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一种化合物，例如用于治疗受试者的代谢紊乱。这些化合物具有一般式I： 其中变量Q、L1、L2、M、X、L3和A的定义在此处提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱的方法，例如II型糖尿病。
• Rhodium-Catalyzed Deoxygenation and Borylation of Ketones: A Combined Experimental and Theoretical Investigation
  作者：Lei Tao、Xueying Guo、Jie Li、Ruoling Li、Zhenyang Lin、Wanxiang Zhao

  DOI：10.1021/jacs.0c07854

  日期：2020.10.21

  The rhodium-catalyzed deoxygenation and borylation of ketones with B2pin2 have been developed, leading to efficient formation of alkenes, vinylboronates, and vinyldiboronates. These reactions feature mild reaction conditions, a broad substrate scope, and excellent functional-group compatibility. Mechanistic studies support that the ketones initially undergo a Rh-catalyzed deoxygenation to give alkenes

  已经开发了铑催化的酮与 B2pin2 的脱氧和硼酸化，从而有效地形成烯烃、乙烯基硼酸酯和乙烯基二硼酸酯。这些反应的特点是反应条件温和，底物范围广，官能团兼容性好。机理研究支持酮最初经过 Rh 催化脱氧以通过硼烯醇化物中间体得到烯烃，随后 Rh 催化的烯烃脱氢硼化导致乙烯基硼酸酯和二硼化产物的形成，这也得到 DFT 计算的支持。
• THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA
  申请人：Baba Masanori

  公开号：US20110172185A1

  公开（公告）日：2011-07-14

  An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R 1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R 2 is an acyl group, a thioacyl group, CONR 7 R 8 , or CSNR 7 R 8 (R 7 and R 8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R 1 and R 2 together may form a ring, X 1 and X 2 may be the same or different and are each —CR 3 R 4 —, —SiR 3 R 4 — or oxygen, and R 3 and R 4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.

  一种提供成人T细胞白血病的新型治疗药物的对象是具有ATL细胞特异性抗肿瘤作用。根据本发明的成人T细胞白血病治疗药物的特征在于含有由式I表示的化合物或其前药， 其中R 1 为H、OH、烷氧基、酰基或硫酰基，R 2 为酰基、硫酰基、CONR 7 R 8 或CSNR 7 R 8 （R 7 和R 8 各自独立地为H、含有1至3个碳原子的烷基或苯基），或R 1 和R 2 可共同形成环，X 1 和X 2 可以相同也可以不同，分别为—CR 3 R 4 —、—SiR 3 R 4 —或氧，R 3 和R 4 可以相同也可以不同，分别为含有1至6个碳原子的烷基。
• Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
  申请人：Tsang Yin Kwok

  公开号：US20050148590A1

  公开（公告）日：2005-07-07

  Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR γ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.

  式中变量的定义如规范中所述，对于预防或治疗哺乳动物的肺气肿和相关肺部疾病以及其他对RARγ激动剂类维生素A酸类药物敏感的疾病和病况是有用的，例如皮肤相关疾病，包括但不限于痤疮和牛皮癣。